Nulojix is prescribed to kidney transplant patients to prevent rejection in transplant patients that have been exposed to Epstein-Barr virus.
Nulojix is an immunosuppressant that suppresses the activity of T-cells which may be involved in organ rejection.
Nulojix works by binding to two molecules CD80 and CD86 that are responsible for activating and stimulating T-cells. By preventing the activation of T-Cells, Nulojix helps prevent organ donor rejection.
Initial dosing schedule: day of transplant and then 4 days, 2 weeks, 4 weeks, 8 weeks, and 12 weeks.
Every 4 weeks after the initial dose.
Before your infusion, it is important to drink plenty of water and come to your appointment hydrated. Additionally, you must alert us as soon as possible to any changes in your insurance to ensure that we are still an in-network provider for your infusion therapy.